Header Logo
Keywords
Last Name
Institution
Announcement

You can now add alternative names! Click here to add other names that you've published under.

Jennifer Laudadio

Concepts (144)

Concept scores are derived automatically based on a person's publications. Keywords in the their attributed publications are matched to keywords from the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). The strength of a person's concept scores is based not only on the number of corresponding publications, but also how relevant the concepts are to the overall topics of the publications, how long ago the publications were written, whether the person was the first or senior author, and how many other people have written about the topic.Concepts cannot be directly edited. You can help ensure your concepts are accurate by making sure your attributed publications are correct and up-to-date. We recommend checking over your attributed publications list every three to four months.

Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.

Name Number of Publications Most Recent Publication Publications by All Authors Concept Score Why?
Papillomavirus Infections
4
2015
168
1.150
Why?
Papillomaviridae
3
2015
103
0.890
Why?
Keratosis, Seborrheic
2
2015
3
0.580
Why?
Vulvar Diseases
2
2015
7
0.570
Why?
Alphapapillomavirus
2
2014
13
0.540
Why?
Pathology
1
2015
38
0.470
Why?
Fusion Proteins, bcr-abl
3
2009
17
0.460
Why?
Curriculum
2
2022
400
0.430
Why?
Genomics
1
2015
279
0.430
Why?
Neoplasm Invasiveness
2
2012
269
0.430
Why?
Uterine Cervical Dysplasia
1
2013
49
0.410
Why?
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
3
2009
45
0.390
Why?
Perineum
1
2012
24
0.390
Why?
Myxoma
1
2012
16
0.390
Why?
Mutagenesis, Insertional
2
2008
22
0.370
Why?
Vulvar Neoplasms
1
2012
58
0.370
Why?
Uterine Cervical Neoplasms
1
2013
276
0.340
Why?
Mass Screening
1
2013
344
0.340
Why?
In Situ Hybridization, Fluorescence
2
2007
231
0.300
Why?
Introns
1
2008
48
0.290
Why?
Protein Kinase Inhibitors
2
2013
204
0.280
Why?
Carcinoma, Squamous Cell
1
2010
326
0.280
Why?
Head and Neck Neoplasms
1
2010
287
0.280
Why?
Genes, erbB-2
1
2007
8
0.280
Why?
Actinomyces
1
2006
10
0.270
Why?
Actinomycosis
1
2006
10
0.270
Why?
Vaginal Smears
1
2006
28
0.270
Why?
Carcinoma, Transitional Cell
1
2005
51
0.240
Why?
Microsatellite Instability
1
2024
19
0.230
Why?
DNA Mismatch Repair
1
2024
16
0.230
Why?
Urinary Bladder Neoplasms
1
2005
158
0.230
Why?
Endometrial Neoplasms
1
2024
137
0.210
Why?
Humans
20
2024
50503
0.200
Why?
DNA, Viral
2
2014
136
0.190
Why?
Polymerase Chain Reaction
2
2014
449
0.180
Why?
Fellowships and Scholarships
1
2022
120
0.180
Why?
Colorectal Neoplasms
1
2024
260
0.180
Why?
Female
13
2024
27081
0.170
Why?
Middle Aged
7
2014
12611
0.150
Why?
Breast Neoplasms
1
2007
1201
0.140
Why?
Gastrointestinal Neoplasms
1
2015
40
0.120
Why?
Prognosis
4
2015
1978
0.120
Why?
Mucositis
1
2014
7
0.120
Why?
Oropharyngeal Neoplasms
1
2014
19
0.110
Why?
Histocytochemistry
1
2014
44
0.110
Why?
Microscopy
1
2014
59
0.110
Why?
Quinazolines
1
2013
32
0.110
Why?
Protein Structure, Tertiary
3
2009
245
0.110
Why?
Human Papillomavirus DNA Tests
1
2013
1
0.110
Why?
Virology
1
2013
7
0.110
Why?
Molecular Diagnostic Techniques
1
2013
33
0.100
Why?
Bile Duct Diseases
1
2013
11
0.100
Why?
United States Food and Drug Administration
1
2013
90
0.100
Why?
Genotype
1
2014
533
0.100
Why?
RNA, Messenger
2
2013
1089
0.100
Why?
Clinical Competence
1
2015
398
0.100
Why?
Phosphotransferases
2
2009
16
0.100
Why?
Aged
5
2014
9741
0.100
Why?
Carcinoma, Non-Small-Cell Lung
1
2013
154
0.090
Why?
Piperazines
2
2009
119
0.090
Why?
Cholelithiasis
1
2011
12
0.090
Why?
Cholecystectomy, Laparoscopic
1
2011
20
0.090
Why?
Pyrimidines
2
2009
191
0.090
Why?
In Situ Hybridization
1
2010
66
0.090
Why?
Smoking
1
2014
507
0.090
Why?
Endosonography
1
2011
94
0.090
Why?
Algorithms
1
2013
625
0.080
Why?
HIV Infections
1
2013
352
0.080
Why?
Diagnosis, Differential
1
2012
1033
0.080
Why?
Exons
1
2008
93
0.070
Why?
United States
2
2022
4955
0.070
Why?
Lung Neoplasms
1
2013
601
0.070
Why?
DNA Mutational Analysis
1
2008
175
0.070
Why?
Adult
6
2022
13577
0.070
Why?
Aged, 80 and over
3
2014
3226
0.070
Why?
Proto-Oncogenes
1
2007
27
0.070
Why?
Base Sequence
1
2008
639
0.070
Why?
Gene Amplification
1
2007
56
0.070
Why?
Amino Acid Sequence
1
2008
574
0.070
Why?
Receptor, erbB-2
1
2007
75
0.070
Why?
Molecular Sequence Data
1
2008
778
0.070
Why?
Male
7
2014
25907
0.060
Why?
Cell Division
1
2007
291
0.060
Why?
Young Adult
2
2013
4102
0.060
Why?
Intestinal Neoplasms
1
2024
8
0.060
Why?
Pathology, Clinical
1
2024
24
0.060
Why?
Immunohistochemistry
1
2007
957
0.060
Why?
Mutation
1
2009
1280
0.050
Why?
Intestine, Small
1
2024
110
0.050
Why?
Antineoplastic Agents
4
2014
1172
0.050
Why?
Sensitivity and Specificity
1
2005
859
0.050
Why?
Retrospective Studies
4
2022
6263
0.050
Why?
Adolescent
3
2011
6443
0.050
Why?
Disease-Free Survival
2
2014
444
0.050
Why?
Esophageal Neoplasms
1
2024
106
0.050
Why?
Pathology, Molecular
1
2022
22
0.050
Why?
Accreditation
1
2022
61
0.050
Why?
Neoplasm Recurrence, Local
1
2005
629
0.050
Why?
Combined Modality Therapy
2
2014
641
0.040
Why?
Reproducibility of Results
1
2024
1197
0.040
Why?
Education, Medical, Graduate
1
2022
217
0.040
Why?
Treatment Outcome
3
2014
5283
0.040
Why?
Benzamides
2
2009
50
0.040
Why?
Molecular Imaging
1
2015
54
0.030
Why?
Cyclin D3
1
2013
5
0.030
Why?
Survival
1
2013
11
0.030
Why?
Taxoids
1
2013
37
0.030
Why?
Cyclin D1
1
2013
52
0.030
Why?
Granulocyte Colony-Stimulating Factor
1
2013
63
0.030
Why?
Radiotherapy
1
2014
125
0.030
Why?
Polyethylene Glycols
1
2013
86
0.030
Why?
Anti-Retroviral Agents
1
2013
13
0.030
Why?
Liver Cirrhosis, Biliary
1
2013
11
0.030
Why?
Jaundice
1
2013
19
0.030
Why?
Patient Compliance
1
2014
233
0.030
Why?
Drug Administration Schedule
1
2013
370
0.030
Why?
Cholestasis
1
2013
40
0.030
Why?
Recombinant Proteins
1
2013
476
0.020
Why?
Syndrome
1
2013
240
0.020
Why?
Cisplatin
1
2013
286
0.020
Why?
CD4-Positive T-Lymphocytes
1
2013
158
0.020
Why?
Technetium Tc 99m Lidofenin
1
2011
1
0.020
Why?
Ursodeoxycholic Acid
1
2011
5
0.020
Why?
Cholagogues and Choleretics
1
2011
6
0.020
Why?
Cholangiography
1
2011
10
0.020
Why?
Cholangiopancreatography, Magnetic Resonance
1
2011
9
0.020
Why?
False Negative Reactions
1
2011
29
0.020
Why?
Ceftriaxone
1
2011
24
0.020
Why?
Age of Onset
1
2011
108
0.020
Why?
Biopsy
1
2013
588
0.020
Why?
Antibiotic Prophylaxis
1
2011
62
0.020
Why?
Radiography, Interventional
1
2011
57
0.020
Why?
Pancreatitis
1
2011
59
0.020
Why?
Neurosurgical Procedures
1
2011
124
0.020
Why?
Gene Expression Regulation, Leukemic
1
2009
29
0.020
Why?
Comorbidity
1
2011
623
0.020
Why?
Up-Regulation
1
2009
446
0.020
Why?
Antineoplastic Combined Chemotherapy Protocols
1
2013
1000
0.020
Why?
Transcription, Genetic
1
2008
361
0.020
Why?
Liver
1
2013
1132
0.020
Why?
Follow-Up Studies
1
2011
2242
0.020
Why?
Tomography, X-Ray Computed
1
2011
1164
0.020
Why?
Postoperative Complications
1
2011
1033
0.010
Why?
Child
1
2011
6906
0.010
Why?
Laudadio's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts Expand Description
_
Co-Authors Expand Description
_
Similar People Expand Description
_